Take it easy there. I realize that many parts of body building are not perfectly healthy and that many people choose to use drugs or supplements that have the potential to harm. I only provided my information because someone was asking about this drug and they didn't seem to know a whole lot about it.
I am not saying don't use it, I am saying be careful and do your research and gather your facts first. It is important to go into things knowing what the risks are...in this case if you have any family history of cancer I think this is a foolish drug choice, but if anyone feels it's worth the risk go right ahead.
Your statment - "if your were to inject 10mg, or 10000mcg.. your blood sugar would drop and you'd probably die."
Is not right either. Here is a link to the drug fact and dosage sheet for IGF-1:
http://www.factsandcomparisons.com/a..._rinfabate.pdf
In there you will see under Administration and Dosage that a maximum of 2mg/kg can be administered per day. This equals 2 mg/2.2 pounds. So, for a small person say 50kg or 110 lbs that would be 100mg per day.
Here is one of many articles that associate increased IGF-1 levels with not only the development of cancer, but also the increased aggressiveness of that cancer. Again, I am only providing information for an informed choice. I thought that's why we have forums like this. Insulting me isn't going to make the risks any different.
"1: Clin Cancer Res. 2005 May 1;11(9):3233-42. Related Articles, Links
Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases.
Furukawa M, Raffeld M, Mateo C, Sakamoto A, Moody TW, Ito T, Venzon DJ, Serrano J, Jensen RT.
Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Hematopathology Section, Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, Maryland 20892-1804, USA.
PURPOSE: Growth factors, particularly insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR) in some nonendocrine and a few endocrine tumors, are thought important in recurrence, growth, and aggressiveness. Whether this is true of neuroendocrine tumors such as gastrinomas is unclear. The aim of this study was to address this question in gastrinomas. EXPERIMENTAL DESIGN: IGF-I and IGF-IR expression in gastrinomas from 54 patients with Zollinger-Ellison syndrome were analyzed and correlated with clinical/tumor characteristics. IGF-I and IGF-IR mRNA levels were determined by competitive reverse transcription-PCR. IGF-IR expression, assessed by immunohistochemistry, was done on a subset. RESULTS: IGF-IR mRNA was found in 100% and IGF-I in 89%. IGF-I mRNA expression varied by >254-fold, IGF-IR by 2,670-fold, and the levels correlated in a given tumor. The IGF-IR level was lower in gastrinomas of patients who were rendered disease free and increased levels correlated with tumor growth, aggressiveness, extent, and with liver metastases. Increased IGF-I levels correlated with increased growth, tumor extent, and aggressiveness. Neither IGF-IR nor IGF-I levels correlated with tumor location, size, or its clinical/functional features. The IGF-IR correlated with disease-free survival. IGF-IRbeta was found in 31 of 32 tumors (97%) by immunohistochemistry. CONCLUSIONS: These results indicate that IGF-I and IGF-IR are expressed in almost all gastrinomas. Furthermore, assessment of IGF-I/IGF-IR expression in gastrinomas may be clinically useful in identifying those patients with more aggressive tumors who might benefit from more aggressive treatment.
PMID: 15867218 [PubMed - indexed for MEDLINE]